SCHEMBL4423693

SCHEMBL4423693

CCc1ccc(S(=O)(=O)N2CC3C(CNc4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 5/20 0.43
THRB P10828 3/20 0.43
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
MAOB P27338 4/20 0.41
TP53 P04637 3/20 0.41
MAOA P21397 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4425278 0.93 ALDH1A1 (0.43) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4415450 0.91 MAOB (0.43) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4417872 0.91 ALDH1A1 (0.45) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4419968 0.91 L3MBTL1 (0.46) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4414984 0.91 MMP1 (0.44) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4425190 0.89 MEN1 (0.46) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4414933 0.89 KMT2A (0.43) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4417782 0.89 MAPT (0.45) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4413584 0.89 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1KMT2ALMNAPOLB
SCHEMBL4419259 0.89 MAOB (0.53) MAPK1SMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAPK1 2572/4885SMN1; SMN2 4003/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.